CytoGam immunoglobulin to prevent late CMV disease after liver or kidney transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4 interventional trial enrolls adult transplant recipients at high risk for late CMV disease (donor CMV seropositive, recipient seronegative) after liver, kidney, or simultaneous liver-kidney transplant. After participants complete standard valganciclovir prophylaxis, they receive intravenous CMV immune globulin (CytoGam) monthly for three months. The study follows participants for evidence of late CMV infection or disease and routine laboratory monitoring, with exclusion of patients with very low kidney function or other non-kidney/liver transplants. The goal is to determine whether adding post-prophylaxis immunoglobulin reduces late CMV complications in this specific high-risk group.

Why it matters

Who can join: the full rules

Inclusion Criteria

* High risk pretransplant CMV donor seropositive/recipient seronegative (D+R-) kidney, liver, or simultaneous liver-kidney (SLK) transplant recipients
* Able to do routine blood testing (normal care for transplant recipients)
* Written informed consent obtained from the subject before any trial-related procedures
* Be ≥18 years and ≤75 years of age at time of consent

Exclusion Criteria

* Any pre-transplant CMV serologic combinations besides CMV D+/R-
* Multi organ transplants (other than simultaneous liver-kidney transplant (SLK) recipients) or prior history of bone marrow or stem cell transplant
* Lung, heart, small bowel, pancreas, or other non-kidney or non-liver transplant recipients
* Transplant recipients treated for rejection within three months before the end of valganciclovir prophylaxis
* Participation in another interventional clinical trial at time of consent or within 30 days prior to study consent
* Transplant recipients with eGFR \<30 ml/min/1.73m2 (as they theoretically could be at higher risk for renal impairment with CMV immunoglobulin), poor transplant organ function (i.e. LFTs \> twice the upper limit of normal in liver recipients), or who are on dialysis, or plasmapheresis, or who are relisted for transplant, or who might otherwise at risk of complications at the discretion of the local site investigator.
* Those with a history of severe reaction to CMV immunoglobulin (e.g. CytoGam® or similar) or other human immunoglobulin preparations
* Individuals with a history of selective immunoglobulin A deficiency will be excluded, as they may produce antibodies against immunoglobulin A, leading to potential anaphylactic reactions upon receiving blood products containing immunoglobulin A, such as CMV immunoglobulin (e.g. CytoGam® or similar)
* Any history of acute myocardial infarction (within 12 months of screening), clinically significant arrythmia, or clinically significant ECG abnormality in the opinion of the investigator at time of screening
* History of active or latent tuberculosis (except those who have completed a documented regimen for latent TB treatment) or severe pulmonary disease \[e.g., severe pulmonary hypertension (WHO class IV)\] that in the opinion of the investigator that may preclude their ability to safely tolerate study infusions
* Any history of neurodegenerative disease, including dementia, or stroke with substantial residual disability (modified Rankin score ≥ 3)
* Pregnant or nursing (lactating) women confirmed by human chorionic gonadotropin (hCG) laboratory test.
* Women of childbearing potential unless using a highly effective method of contraception during dosing and for 24 weeks after study treatment. Medically acceptable birth control (contraceptives) includes but are not limited to: surgical sterilization (such as hysterectomy or "tubes tied"), approved hormonal contraceptives (such as birth control pills, patch or ring; Depo-Provera, Depo-Lupron, lmplanon), barrier methods (such as condom or diaphragm), an intrauterine device (IUD), abstinence from sex.
* Any significant history of any treatment nonadherence or any other medical condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk
* Subjects who have any of the following laboratory values: eGFR \<30 ml/min/1.73m2 ; Hemoglobin \<8.0 g/dL; Platelets \<50,000 cells/uL; Absolute neutrophil count \<1,000 cells/uL; Total bilirubin \>2.5 x upper limit of normal; Alanine aminotransferase (ALT) \>5 x upper limit of normal; Aspartate aminotransferase (AST)\] \>5 x upper limit of normal; CMV IgG negative in donor or positive in recipient

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting
• University of Texas Southwestern
  Dallas, Texas, United States Recruiting

Study contacts

• Principal investigator: Camille Kotton, MD, FIDSA, FAST — Massachusetts General Hospital
• Study coordinator: Amelia Stocking, BS
• Email: astocking@mgh.harvard.edu
• Phone: 617-643-4087

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)

  This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.

  Recruiting Vivalyx GmbH · Rotterdam · NCT07792317

• How Propofol and Sevoflurane Affect miRNA in Living Kidney Donors

  This study tests whether using propofol or sevoflurane during donor nephrectomy changes levels of miRNAs in living kidney donors.

  Recruiting University of Gaziantep · Gaziantep, Sahinbey · NCT07760402

• Effects of general vs spinal-epidural anesthesia on kidney transplant biomarkers

  This study tests whether sevoflurane general anesthesia or combined spinal-epidural anesthesia changes markers of cellular stress and protective peptides in adults undergoing kidney transplantation.

  Recruiting University of Gaziantep · Gaziantep, State/Province · NCT07678073

• How kidney transplant patients feel about using artificial intelligence in medicine

  This international survey asks adults who have had a kidney transplant how they feel about AI tools that predict graft loss and what it might mean for their daily care.

  Recruiting at 2 sites Paris Translational Research Center for Organ Transplantation · Paris, Île-de-France Region and 1 other locations · NCT07600541

• Personalized therapeutic stories for children after kidney transplant.

  We will test whether clinician-supervised AI can create age-appropriate, personalized therapeutic stories for children aged 5–12 who have received a kidney transplant and their families.

  Recruiting Paris Translational Research Center for Organ Transplantation · Paris, Île-de-France Region · NCT07532382

• Treating blood vessel problems after a kidney transplant

  This effort will try catheter-based angioplasty and advanced imaging to see if they help kidney transplant recipients with graft dysfunction or stubborn high blood pressure from possible transplant blood‑vessel problems.

  Recruiting at 3 sites University of Aarhus · Aarhus and 2 other locations · NCT07531966

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.